This new 40,000 m2 built up plant, of a total of 80,000 m2 area, featuring a workforce of 125 people and a production volume of 160 m3, has involved an investment of 40 million Euros and has become ESTEVE’s most important center in China. In addition to production premises, an office building accommodates the Finance, Purchasing, Logistics and Human Resources Departments, as well as a R&D center for process development and the Quality Department. The production of this new plant, located 200 km South of Shanghai in the city of Shaoxing (province of Zhejiang), will be mainly destined for the demanding markets of USA, Europe and Japan, and also represents a great opportunity to serve the expanding Chinese pharmaceutical marketplace.
The Shaoxing center is the result of a joint venture between Esteve Química and Yiwu Huayi Investment –a subsidiary of Huadong Pharmaceutical Group, a leading company in the province of Zhejiang. This agreement led to the creation of Esteve Huayi Pharmaceutical (EHP) in 2005 (61% shareholding by ESTEVE).
These new facilities strengthen ESTEVE’s presence in China and are consistent with the Company’s strategy for fostering activities at the international level, as gathered in Esteve’s 2015 vision (international sales amounting to 66% of total turnover in 2015), and also for reinforcing our presence in the fine chemistry market worldwide.
ESTEVE, in China since 2001
ESTEVE’s presence in China dates back to the year 2000, where Esteve Química and the same partner, Yiwu Huayi Investment, initiated their first joint-venture and opened a factory of intermediate products and pharmaceutical active ingredients in the city of Yiwu, 300 km South of Shanghai. With a surface of 73,000 m2, a production volume of 270 m3 and a staff of 255 people, the production of this center is destined for local and export markets.
About Esteve Química
Esteve Química (EQ) is the company of the group committed to the development, manufacture and international marketing of pharmaceutical active ingredients. In addition to the two centers in China, EQ has two production plants in Spain (Celrà and Banyeres del Penedés) and, through its subsidiary Sintenovo, another two centers for the production of active ingredients in Mexico (Naucalpan y Jiutepec). Its headquarters and R&D facilities are located in Barcelona, Spain.
About ESTEVE
ESTEVE is a Spanish chemical-pharmaceutical group with significant international presence. Founded in 1929, its present activities are devoted to the pharmaceutical area, including: research and development of new drugs, mainly in the field of pain management; marketing of a wide range of prescription products, OTCs, vaccines, generic drugs and veterinary drugs. Also involved in the manufacture and marketing of active pharmaceutical ingredients, ESTEVE thus offers a global response in the healthcare sector. Esteve markets products worldwide and owns facilities in Europe, Asia and North America.
More information at: Angels Valls, Communication Esteve, avalls@esteve.es. Tel. +34 3 446 60 00 Silvia Castells, Grup Inforpress, scastells@inforpress.es, Tel. + 34 3 419 06 30
www.esteve.com
